S&P 500 Technology Sector SEC Filings — March 31, 2026

31-03-2026

Genco Shipping & Trading Ltd (GNK) filed a DEFA14A additional proxy statement on March 31, 2026, in connection with soliciting proxies for its 2026 Annual Meeting of Shareholders, urging use of the WHITE proxy card and referencing upcoming definitive proxy materials. The filing identifies independent directors (Paramita Das, Kathleen C. Haines, Basil G. Mavroleon, Karin Y. Orsel, Arthur L. Regan) and executives (John C. Wobensmith, Peter Allen, Joseph Adamo, Jesper Christensen) as solicitation participants, with details on their interests available in prior proxy statements and recent Form 4 filings. The company expresses confidence in executing a disciplined plan delivering strong results and superior shareholder value in 2026 and beyond, while noting risks around a non-binding indicative proposal from Diana and dividend discretion.

• ·Prior proxy statement for 2025 Annual Meeting filed April 9, 2025.
• ·Form 4 filings for directors and executives on dates including May 22, 2025; June 3, 2025; August 26, 2025; November 2025 dates; February 18, 2026; February 23, 2026; March 20, 2026.
• ·Investor relations website: https://investors.gencoshipping.com/
• ·SEC website: www.sec.gov

31-03-2026

TXNM Energy, Inc. notified holders of its 5.75% Junior Subordinated Convertible Notes due 2054 that they are convertible at the holder's option from April 1, 2026, to June 30, 2026, at a rate of 22.5382 shares per $1,000 principal (equivalent to approx. $44.37 per share), triggered by the common stock price exceeding 130% of the conversion price. Upon conversion, holders receive an equal principal amount of newly issued 5.75% non-convertible junior subordinated notes due 2054 (potentially less liquid and trading below par) plus common stock for any excess obligation. The filing references a pending merger with affiliates of Blackstone Infrastructure Partners L.P. at $61.25 per share, which could trigger special conversion rights if consummated.

• ·Conversion observation period: 60 consecutive trading days beginning second trading day after conversion date.
• ·Merger conversion right: Available from effective date until 35 trading days after, payable solely in cash based on merger price.
• ·Merger conditions include regulatory approvals from Public Utility Commission of Texas, New Mexico Public Regulation Commission, FERC, NRC, and HSR Act.

31-03-2026

First Northern Community Bancorp announced a new stock repurchase program approved by its Board of Directors effective March 26, 2026, set to begin on May 1, 2026, and remain in effect until April 30, 2028. The program authorizes repurchases of up to 6% of its 16,409,660 outstanding common shares as of March 26, 2025, equating to 984,579 shares, or approximately $15.6M at the March 26, 2026 closing price of $15.85 per share. The Board determined that maximum repurchases will not impair the company's capital, with transactions to comply with SEC Rule 10b-18.

• ·Press release issued March 30, 2026 and furnished as Exhibit 99.1
• ·Repurchases may be made in open market or privately negotiated transactions based on market conditions

31-03-2026

ISQ Open Infrastructure Co LLC reported total net assets of $35,591,938 as of December 31, 2025, following $29,485,000 in capital contributions from share issuances since its funding date of March 28, 2025. The company achieved a net increase in net assets from operations of $6,698,504, driven by $7,758,958 in net unrealized gains (net of deferred taxes), resulting in total returns of 20.20% to 33.44% across share classes. However, it recorded a net investment loss of $1,060,454 due to high expenses (11.60%-17.59% before support, 4.30%-5.78% after manager expense support of $1,930,052), including significant allocations from ISQ Open Infrastructure Company LLC - Series II.

• ·Net asset value per share ranged from $30.05 (F-STE) to $33.36 (ETE) at December 31, 2025.
• ·Proceeds from issuance of shares were at $25.00 per share across classes, with minor premiums/discounts.
• ·Manager provided total expense support of $642,214, expiring December 31, 2030.
• ·No shares redeemed or reinvested under DRIP during the period; all shares issued post-formation.
• ·Net cash used in operating activities: $(29,478,000), offset by financing inflows.

31-03-2026

BlockchAIn Digital Infrastructure, Inc. (AIB) reported Successor results for the year ended December 31, 2025, with cost of revenues at $15,001,351 (up slightly from Predecessor full-year 2024 equivalent), gross profit of $3,515,261 at 19% margin (down significantly from Predecessor 37% for Feb-Dec 2024 and 25% for Jan-Feb 2024), and a net loss of $835,431 versus Predecessor profits. Adjusted EBITDA was positive at $1,695,535 (down from $6,171,950 Predecessor Feb-Dec 2024), supported by $2,335,959 in net cash from operating activities, though ending cash balance dwindled to $15,265. The filing highlights risks from customer financial distress and details multiple related-party agreements post-acquisition.

• ·Transaction costs of $1,731,016 in Successor 2025 (vs $76,250 Predecessor Feb-Dec 2024).
• ·Net cash used in financing activities: $(2,506,729) Successor 2025.
• ·Multiple standstill and services agreements with Blue Ridge Digital Mining, LLC and Merkle Standard LLC in 2025.
• ·Cash beginning of year for Successor: $131,107; Predecessor Jan-Feb: $4,722,904.

31-03-2026

Immunic, Inc. (Nasdaq: IMUX) appointed Jon Congleton, a biopharmaceutical executive with nearly 40 years of experience including key roles in the U.S. launch of Copaxone® for multiple sclerosis and current CEO of Mineralys Therapeutics, Inc., to its Board of Directors effective March 27, 2026. This move aims to strengthen leadership expertise in CNS and commercialization as the company advances vidofludimus calcium (IMU-838) through phase 3 trials for relapsing multiple sclerosis, with top-line data expected by end of 2026. No financial impacts or performance metrics were disclosed.

• ·Appointment effective March 27, 2026
• ·Top-line data for IMU-838 phase 3 trials in relapsing MS expected by end of 2026
• ·Jon Congleton's experience: nearly 40 years in biopharmaceuticals, including U.S. neuroscience business at Teva

31-03-2026

Camden National Corporation declared a quarterly dividend of $0.42 per share, payable on April 30, 2026, to shareholders of record on April 15, 2026. The announcement was issued via press release on March 31, 2026, as part of an 8-K filing.

• ·Filing includes Exhibit 99.1: Press Release Dated March 31, 2026
• ·Common Stock traded on The NASDAQ Stock Market LLC under symbol CAC

31-03-2026

Creative Media & Community Trust Corporation filed Articles of Amendment to its charter effecting a 1-for-10 reverse stock split of its common stock, changing the par value from $0.001 to $0.010 per share, effective at 11:58 p.m. ET on March 25, 2026. No fractional shares will be issued, with cash payments in lieu based on the NASDAQ closing price on the effective date. The amendment was duly advised by the Board of Directors and approved by stockholders, with no change to the number of authorized shares.

• ·Articles of Amendment signed on March 23, 2026
• ·SEC 8-K filing date: March 31, 2026
• ·Involves Items 5.03 and 9.01 of Form 8-K

31-03-2026

Acadia Realty Trust's DEF 14A proxy statement announces the virtual annual shareholder meeting on May 13, 2026, at 1:00 p.m. EDT, for electing eight trustees, ratifying Deloitte & Touche LLP as independent auditors for the fiscal year ending December 31, 2026, and approving on a non-binding advisory basis the compensation of Named Executive Officers. The record date is March 16, 2026, with 131,067,861 common shares outstanding entitled to one vote each. The Board recommends voting 'FOR' all proposals.

• ·Meeting held virtually via live webcast at www.virtualshareholdermeeting.com/AKR26
• ·Quorum requires holders of a majority of votes entitled to be cast
• ·Majority of votes cast required for trustee elections, auditor ratification, and advisory compensation approval; abstentions and broker non-votes do not count as votes cast

31-03-2026

Planet Image International Ltd (YIBO) filed its 20-F annual report for the year ended December 31, 2025, providing period-end and average exchange rates for RMB, EUR, and GBP against USD, showing RMB weakening slightly from US$1=RMB7.1891 (2024) to US$1=RMB7.0175 (2025). The report details compliant operations of subsidiaries including Jiangxi Yibo, Yantuo, Jiangxi Leibotai, and Planet Image Shenzhen, focused on printer consumables production, sales, and exports. It highlights key risks such as obsolete inventories from OEM upgrades, export regulation vulnerabilities, dividend payout restrictions from PRC subsidiaries, and potential PRC resident enterprise tax classification.

• ·Sponsored advertisements defined as cost-per-click solution using keyword, product, and interest targeting.
• ·All listed subsidiaries have completed record-filing for customs declaration entities where required.
• ·Risks referenced on pages 10, 12, 25, and 30 of the annual report.

31-03-2026

Green Planet Bio Engineering Co. Ltd. (GPLB) reported a net loss of $35,842 for the year ended December 31, 2025, slightly higher than the $35,544 loss in 2024, driven by stable administrative expenses of $35,842 versus $35,544. The company had no revenue, zero cash balances in both years, and total liabilities rose 7.7% to $500,976 from $465,134, with stockholders' deficit widening to match. Funding came entirely from related party advances, increasing to $484,678 from $459,634.

• ·Net operating loss carryover increased to $276,494 at Dec 31, 2025 from $267,175 at Dec 31, 2024.
• ·No cash flows from operating activities improved slightly in usage to $(36,544) from $(35,044), offset exactly by financing from related party.
• ·No interest or income taxes paid in either year.
• ·Auditor: Stephano Slack LLC since 2025.

31-03-2026

Aditxt, Inc.'s total assets declined 49% YoY to $16,516,781 as of December 31, 2025, driven by a 76% drop in Investment in Evofem to $6,646,056, while fixed assets net decreased to $880,241 from $1,547,774. However, cash surged 284% to $3,198,599, total current assets rose 91% to $3,821,735, total liabilities fell 47% to $12,563,099, and total stockholders' equity increased 262% to $3,953,682. The accumulated deficit widened to $(209,808,770) from $(168,094,569), reflecting ongoing losses.

• ·Common shares outstanding increased dramatically to 411,499 from 193, indicating significant dilution.
• ·Mandatorily Redeemable A-1 Preferred Stock at $779,049 (678 shares) in 2025, none in 2024.
• ·Convertible notes receivable at fair value appeared at $3,899,859 in 2025, none in 2024.

31-03-2026

Jaws Mustang Acquisition Corp reported a net loss of $1,553,158 for the year ended December 31, 2025, compared to net income of $1,682,254 in 2024, driven by a $1,116,750 unfavorable change in fair value of warrant liabilities and sharply lower interest income of $26,223 versus $554,770. Cash balances declined significantly to $60,829 from $319,207, total assets fell to $1,137,801 from $1,373,470, and shareholders' deficit worsened to $(7,134,163) from $(5,554,782), though general and administrative expenses decreased to $462,631 from $1,354,320 and cash in the trust account rose slightly to $1,061,576 from $1,035,353.

• ·Class A ordinary shares subject to possible redemption reduced to 89,480 shares at $11.86 per share as of December 31, 2025 (from implied higher in 2024 at $11.57 per share).
• ·Promissory notes to related parties increased to $1,822,000 from $1,400,000.
• ·Warrant liabilities rose to $2,233,500 from $1,116,750 due to change in fair value.

31-03-2026

Millburn Multi-Markets Fund L.P. reported a net loss of $5,224,098 for the year ended December 31, 2025, compared to net income of $9,205,893 in 2024, driven by net realized and unrealized losses of $5,545,733 allocated from the Master Fund versus gains of $7,853,428. Total assets declined 15.8% to $103,171,727 from $122,530,334, with partners’ capital dropping to $102,624,923 from $121,077,762; NAV per unit fell across all series, with total returns ranging from -1.27% to -4.91%. The Master Fund experienced a sharper contraction, with total assets at $294,405,991 (down from $437,719,149) and a net loss of $10,472,013 versus profit of $37,760,803.

• ·Capital contributions in 2025: $325,253 (Series B: $200,000; Series E: $125,253)
• ·Capital withdrawals in 2025: $13,553,994 across series
• ·Net investment income 2025: $322,912 (down from $1,452,531 in 2024)
• ·Master Fund net unrealized appreciation on futures and forwards as % of partners’ capital: 1.15% (Dec 31, 2025)
• ·Series A units outstanding declined from 79,074.9857 to 71,137.2609

31-03-2026

Richmond Mutual Bancorporation, Inc. (RMBI) and The Farmers Bancorp, Frankfort, Indiana entered a merger agreement on November 11, 2025, under which Farmers Bancorp will merge into RMBI, creating a combined bank holding company with approximately $2.6 billion in total assets, $224.7 million market capitalization, and 25 branches across Indiana and Ohio. Farmers Bancorp shareholders will receive 3.40 shares of RMBI common stock per Farmers share, valued at $46.07 per share or $85.0 million aggregate based on RMBI's March 30, 2026 closing price of $13.55, with RMBI issuing about 6,269,855 shares and former Farmers shareholders owning 38% of the combined company. Shareholder votes are set for Farmers Bancorp's special meeting on May 26, 2026, and RMBI's annual meeting on May 27, 2026, with both boards unanimously recommending approval.

• ·Exchange ratio: 3.40 RMBI shares per Farmers Bancorp share.
• ·Merger agreement dated November 11, 2025.
• ·RMBI closing price November 11, 2025 (last trading day before announcement): implied value of $44.71 per Farmers share.
• ·RMBI closing price March 30, 2026: $13.55.
• ·Farmers Bancorp special meeting: May 26, 2026, 9:00 a.m. ET.
• ·RMBI annual meeting: May 27, 2026, 9:00 a.m. ET.
• ·Merger expected to qualify as tax-free reorganization under IRC Section 368(a).

31-03-2026

Reading International reported FY 2025 total revenue of $203.0 million, down 3.6% from $210.5 million in 2024, with operating loss narrowing to $5.3 million from $14.0 million and net loss improving to $14.1 million from $35.3 million. While cinema Q4 revenue fell 14% to $46.9 million and operating income dropped 76% to $0.9 million due to weaker film slate and closures, full-year cinema operating income surged to $3.6 million from a $2.8 million loss, driven by cost reductions and record ATP and F&B SPP; real estate operating income rose to $5.9 million from $4.7 million despite 8% revenue decline from asset sales. The company sold Wellington NZ properties for $21.5 million and Cannon Park AU for $20.7 million, using proceeds to reduce debt by $32.1 million, and acquired full ownership of Cinemas 123.

• ·Acquired 100% interest in Cinemas 123 via purchase of Sutton Hill Associates on Dec 19, 2025.
• ·Multiple loan extensions in 2025-2026, including NAB to Jul 31, 2030 and 44 Union Square to Nov 6, 2026 (extendable to May 6, 2027).
• ·Under contract to sell Napier NZ property with cinema leaseback.
• ·Engaged Newmark to sell Cinemas 123 property.
• ·Pre-recorded earnings call webcast scheduled for posting by Apr 2, 2026.

31-03-2026

Planet Green Holdings Corp. (PLAG) reported net revenues of $3,040,616 for the year ended December 31, 2025, a 35% decline from $4,692,664 in 2024, with gross profit plummeting 82% to $100,937 amid sharply higher general and administrative expenses of $17,641,990 (up 476%). The company posted a net loss of $26,975,710, more than tripling from $7,329,056 in 2024, leading to total assets shrinking to $10,209,878 from $25,416,978 and stockholders' equity turning negative at $(2,170,043). Losses from discontinued operations worsened to $9,184,214 from $4,755,970.

• ·Net cash used in operating activities: $(1,786) thousand in 2025 vs $812 thousand provided in 2024.
• ·Stock-based compensation issued 6,950,000 shares valued at $14,429,500.
• ·Equity compensation plans: 50,000 securities remaining available for future issuance.

31-03-2026

IMUNON reported 2025 net loss of $14.5 million, improved from $18.6 million in 2024, with operating expenses down 23% to $14.7 million driven by 33% lower R&D and 8% lower G&A expenses following a strategic reorganization to cut costs. Final Phase 2 OVATION 2 data showed continued overall survival improvement with IMNN-001, increasing to a 14.7-month median benefit (45.1 vs. 30.4 months) vs. standard chemotherapy alone and 24.2 months (65.6 vs. 41.4 months) with PARP inhibitors; Phase 3 OVATION 3 enrollment remains ahead of plan. Cash and equivalents stood at $8.8 million as of December 31, 2025, after $17.1 million from financings including a $7.0 million registered direct offering.

• ·1,939,114 shares (or pre-funded warrants) sold at $3.61 combined price per share and warrant in December 2025 offering; warrants exercisable at $3.482/share, expire in 5 years.
• ·First patient dosed in Phase 3 OVATION 3 in Q3 2025.

31-03-2026

Canton Strategic Holdings, Inc. filed an 8-K on March 31, 2026, announcing via press release its financial results for the full year ended December 31, 2025. The press release is furnished as Exhibit 99.1. No specific financial metrics or period-over-period comparisons are detailed in the filing itself.

• ·Filing includes Items 8.01 (Other Events) and 9.01 (Financial Statements and Exhibits).
• ·Registrant is an emerging growth company.
• ·Common stock trades as CNTN on Nasdaq.
• ·Principal executive offices: 34 Shrewsbury Avenue, Suite 1C, Red Bank, NJ 07701.

31-03-2026

ImmunityBio secured $75 million in non-dilutive financing under its existing Revenue Interest Purchase Agreement (RIPA) with Oberland Capital, increasing total committed capital to $375 million, while Nant Capital converted $25 million of a $505 million promissory note into 4.6 million shares of common stock. These transactions strengthen the balance sheet to support global expansion following ANKTIVA approvals across five jurisdictions covering 34 countries since April 2024. No declines or flat metrics were reported.

• ·ANKTIVA approvals: US (FDA, April 2024), UK (MHRA, July 2025), Saudi Arabia (SFDA, January 2026 for NMIBC CIS and NSCLC), EU (February 2026 covering 27 member states plus Iceland, Norway, Liechtenstein), Macau SAR (March 2026)
• ·Global regulatory footprint of 34 countries established in under two years from initial US FDA approval

31-03-2026

Snowflake Inc. appointed Jonathan Beaulier as Chief Revenue Officer effective March 31, 2026, succeeding Michael Gannon, who is departing for personal reasons and will provide transitional consulting services under a separation agreement that includes cash payments and continued vesting of equity awards. The appointment represents an internal promotion, with Beaulier previously serving as GVP, U.S. Majors Sales since August 2024. The company reaffirmed its previously issued guidance for Q1 and full-year fiscal 2027, originally provided on February 25, 2026.

• ·Beaulier, age 49, previously served as VP of Sales – Financial Services & Insurance from February 2022 to August 2024 and holds a B.A. in History and Economics from Colgate University.
• ·The press release is furnished as Exhibit 99.1.

31-03-2026

Cadiz Inc's total revenues rose 69.8% YoY to $16,313 thousand in 2025 from $9,608 thousand, primarily driven by an 83.3% increase in Water Filtration Technology revenues to $14,478 thousand, while Land and Water Resources revenues grew modestly 7.4% to $1,835 thousand. However, total costs and expenses increased 27.6% to $41,911 thousand, widening the operating loss to $25,598 thousand from $23,249 thousand and the net loss to $34,151 thousand from $31,140 thousand. Cash and equivalents declined to $8,599 thousand from $17,292 thousand, with stockholders' equity dropping to $23,256 thousand from $33,961 thousand.

• ·Basic and diluted net loss per common share improved to $(0.48) from $(0.53).
• ·Net cash used in operating activities decreased to $18,930 thousand from $21,532 thousand.
• ·Long-term debt, net increased to $72,705 thousand from $56,708 thousand.
• ·Total assets grew to $140,914 thousand from $134,494 thousand.
• ·Preferred stock dividend requirements $5,083 thousand in 2025 vs $5,106 thousand in 2024.

31-03-2026

Mills Music Trust's 2025 top revenue-generating songs were led by 'SLEIGH RIDE (VOCAL)' at $1,190,557.59 and 'LITTLE DRUMMER BOY' at $1,073,052.22, with the top nine songs collectively generating over $3.6 million in gross revenue. Notable performers included 'SLEIGH RIDE PROMENADE' ($365,657.56) and 'On The Sunny Side Of The Street' ($296,430.01). However, several key songs such as 'On The Sunny Side Of The Street' (public domain 2026), 'SLEIGH RIDE PROMENADE' (2028), and others are approaching the end of their copyright terms, which could lead to future revenue declines.

• ·Song copyrights expire in 2025 ('On The Sunny Side Of The Street'), 2027 (multiple songs), 2030, 2032, and 2045
• ·US Public Domain entry years: 2026, 2028, 2031, 2033, 2046
• ·Filing Date: March 31, 2026

31-03-2026

The Federal Home Loan Bank of San Francisco disclosed under Item 2.03 the commitment to issue a consolidated obligation bond (CUSIP 3130BA5N3) for which it is the primary obligor, with a par value of $10,000,000, a fixed coupon rate of 4.130%, settlement on April 6, 2026, maturity on July 3, 2030, and an optional European-style principal redemption call on July 3, 2028. This bond is part of routine funding through capital markets sales of consolidated obligations, which are joint and several liabilities of the eleven Federal Home Loan Banks, backed solely by their resources and not by the U.S. government. The filing notes that such issuances are material overall but does not assess materiality of individual obligations, and excludes short-term discount notes and derivatives.

• ·Trade date: March 26, 2026
• ·Settlement date: April 6, 2026
• ·Maturity date: July 3, 2030
• ·Next pay date: July 3, 2026
• ·Next call date: July 3, 2028
• ·Call type: Optional Principal Redemption
• ·Call style: European

31-03-2026

Adia Nutrition, Inc. reported total revenue of $700,508 for the year ended December 31, 2025, a massive 10,885% YoY increase from $6,380 in 2024, primarily driven by new sales of biologics ($443,750 or 63.3%) and medical procedures ($245,600 or 35.1%). However, sales of supplements declined 47% YoY to $3,393, operating expenses more than tripled to $558,162 from $176,943, cost of revenue surged to $508,838, and all segments except ADIA Labs reported losses, resulting in an overall segment loss.

• ·Company qualifies as a 'smaller reporting company' with annual revenues under $100 million.
• ·ADIA Labs was the only profitable segment in 2025 with $148,783 profit; Corporate Overhead loss of $316,139, ADIA Med loss of $198,889.
• ·Gross profit for 2025 was $191,670, up significantly from $2,194 in 2024.

31-03-2026

SEALSQ Corp reported net sales of $18,252 thousand for FY2025, up 66% YoY from $10,981 thousand in FY2024, with North America contributing 57% ($10,487 thousand) despite a decline in share from 68%. However, operating expenses surged 132% to $48,429 thousand, leading to an operating loss of $39,799 thousand (up 132% YoY) and net loss of $34,194 thousand (61% wider YoY), while sales remained below FY2023's $30,058 thousand. Non-GAAP EBITDA improved slightly to -$37.6 million from -$16.6 million but stayed deeply negative.

• ·Europe, Middle East & Africa net sales: $4,444 thousand (24%) in FY2025, up from $1,839 thousand (17%) in FY2024.
• ·Asia Pacific net sales: $3,227 thousand (18%) in FY2025, up from $1,642 thousand (15%) in FY2024.
• ·Research & development expenses: $12,477 thousand in FY2025, up 150% YoY.
• ·Selling & marketing expenses: $12,768 thousand in FY2025, up 134% YoY.
• ·General & administrative expenses: $25,791 thousand in FY2025, up 138% YoY.